Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials

INTRODUCTION: Turoctocog alfa pegol is a glycoPEGylated recombinant factor VIII (FVIII) with an extended half‐life developed for prophylaxis, treatment of bleeds and perioperative management in patients with haemophilia A. AIM: Evaluate the efficacy and safety of turoctocog alfa pegol treatment for...

Descripción completa

Detalles Bibliográficos
Autores principales: Tosetto, Alberto, Neff, Anne, Lentz, Steven R., Santagostino, Elena, Nemes, Laszlo, Sathar, Jameela, Meijer, Karina, Chowdary, Pratima, Shen, Chunduo, Landorph, Andrea, Hampton, Kingsley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317207/
https://www.ncbi.nlm.nih.gov/pubmed/32293786
http://dx.doi.org/10.1111/hae.13980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317207/
https://www.ncbi.nlm.nih.gov/pubmed/32293786
http://dx.doi.org/10.1111/hae.13980

Ejemplares similares